Here is an overview on what the numbers suggest is the one of the cheapest robotic medical device manufacturers today, Stereotaxis (NASDAQ: STXS). Look for revenue growth to resume for STXS in 2014 and beyond driven by entry into Japan as well as VDrive approval helping close significant discount to peers.
Stereotaxis Raised Capital At Significantly Higher Valuations When It Was A Private Company When Growth Expectations Were High But Overall Sales Were Low. Look For Expectations For Growth To Resume Off Significantly Higher Revenue Base Which Should Drive Valuation Higher Once Again As Balance Sheet No Longer At Risk.
Before Stereotaxis went public in 2004, it raised $127 million as a private company with several strategic investors including...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: